1. Home
  2. MPWR vs REGN Comparison

MPWR vs REGN Comparison

Compare MPWR & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Monolithic Power Systems Inc.

MPWR

Monolithic Power Systems Inc.

HOLD

Current Price

$1,543.64

Market Cap

66.5B

Sector

Technology

ML Signal

HOLD

Logo Regeneron Pharmaceuticals Inc.

REGN

Regeneron Pharmaceuticals Inc.

HOLD

Current Price

$749.36

Market Cap

77.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MPWR
REGN
Founded
1997
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
66.5B
77.5B
IPO Year
2004
1995

Fundamental Metrics

Financial Performance
Metric
MPWR
REGN
Price
$1,543.64
$749.36
Analyst Decision
Strong Buy
Buy
Analyst Count
14
25
Target Price
$1,137.21
$827.76
AVG Volume (30 Days)
464.5K
525.9K
Earning Date
04-30-2026
04-29-2026
Dividend Yield
0.54%
0.50%
EPS Growth
N/A
8.19
EPS
12.86
41.48
Revenue
$333,067,000.00
$5,872,227,000.00
Revenue This Year
$23.89
$12.45
Revenue Next Year
$17.62
$10.13
P/E Ratio
$115.44
$18.04
Revenue Growth
17.89
20.82
52 Week Low
$532.79
$476.49
52 Week High
$1,492.50
$821.11

Technical Indicators

Market Signals
Indicator
MPWR
REGN
Relative Strength Index (RSI) 80.36 46.75
Support Level $899.99 $732.04
Resistance Level N/A $787.20
Average True Range (ATR) 45.76 16.63
MACD 30.06 -0.78
Stochastic Oscillator 95.07 32.09

Price Performance

Historical Comparison
MPWR
REGN

About MPWR Monolithic Power Systems Inc.

Monolithic Power Systems is an analog and mixed-signal chipmaker specializing in power management solutions. Its mission is to reduce total energy consumption in end systems. It serves the computing, automotive, industrial, communications, and consumer end markets. MPS uses a fabless manufacturing model, partnering with third-party chip foundries to host its proprietary BCD process technology.

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Share on Social Networks: